Toxicity of oligodeoxynucleotide therapeutic agentsLEVIN, A. A; MONTEITH, D. K; LEEDS, J. M et al.Handbook of experimental pharmacology. 1997, Vol 131, pp 169-215, issn 0171-2004Article

Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley ratsHENRY, S. P; GRILLONE, L. R; ORR, J. L et al.Toxicology (Amsterdam). 1997, Vol 116, Num 1-3, pp 77-88, issn 0300-483XArticle

Toxicological properties of several novel oligonucleotide analogs in miceHENRY, S. P; ZUCKERMAN, J. E; ROJKO, J et al.Anti-cancer drug design. 1997, Vol 12, Num 1, pp 1-14, issn 0266-9536Article

Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotidesGEARY, R. S; LEEDS, J. M; HENRY, S. P et al.Anti-cancer drug design. 1997, Vol 12, Num 5, pp 383-393, issn 0266-9536Article

Expression of human aldose and aldehyde reductases : site-directed mutagenesis of a critical lysine 262BOHREN, K. M; PAGE, J. L; SHANKAR, R et al.The Journal of biological chemistry (Print). 1991, Vol 266, Num 35, pp 24031-24037, issn 0021-9258Article

Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeysLEEDS, J. M; HENRY, S. P; BISTNER, S et al.Drug metabolism and disposition. 1998, Vol 26, Num 7, pp 670-675, issn 0090-9556Article

Antisense oligonucleotide inhibitors for the treatment of cancer : 2. Toxicological properties of phosphorothioate oligodeoxynucleotidesHENRY, S. P; MONTEITH, D; LEVIN, A. A et al.Anti-cancer drug design. 1997, Vol 12, Num 5, pp 395-408, issn 0266-9536Article

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeysHENRY, S. P; BOLTE, H; AULETTA, C et al.Toxicology (Amsterdam). 1997, Vol 120, Num 2, pp 145-155, issn 0300-483XArticle

Hierarchical regulation by casein kinases I and II of the activation of protein phosphatase-1_i by glycogen synthase kinase-3 is ionic strength dependentHENRY, S. P; KILLILEA, S. D.Archives of biochemistry and biophysics (Print). 1993, Vol 301, Num 1, pp 53-57, issn 0003-9861Article

Preclinical development of antisense therapeuticsLEVIN, A. A; HENRY, S. P; BENNETT, C. F et al.Handbook of experimental pharmacology. 1999, Vol 137, pp 131-163, issn 0171-2004Article

Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1HENRY, S. P; TEMPLIN, M. V; GILLETT, N et al.Toxicologic pathology. 1999, Vol 27, Num 1, pp 95-100, issn 0192-6233Conference Paper

Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-α and C-raf kinaseHENRY, S. P; MONTEITH, D; BENNETT, F et al.Anti-cancer drug design. 1997, Vol 12, Num 5, pp 409-420, issn 0266-9536Article

Immune stimulation : a class effect of phosphorothioate oligodeoxynucleotides in rodentsMONTEITH, D. K; HENRY, S. P; HOWARD, R. B et al.Anti-cancer drug design. 1997, Vol 12, Num 5, pp 421-432, issn 0266-9536Article

Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbitLEEDS, J. M; HENRY, S. P; TRUONG, L et al.Drug metabolism and disposition. 1997, Vol 25, Num 8, pp 921-926, issn 0090-9556Article

Cardiac hypertrophy in rats after intravenous administration of CI-959, a novel antiinflammatory compound : morphologic features and pharmacokinetic and pharmacodynamic mechanismsLOW, J. E; METZ, A. L; GOUGH, A. W et al.Journal of cardiovascular pharmacology. 1995, Vol 25, Num 6, pp 930-939, issn 0160-2446Article